FDA Approves Tiziana’s Phase 2 Trial for Multiple System Atrophy
Tiziana Life SciencesLife Sciences has received FDA clearance for a Phase 2a trial of intranasal foralumab in patients with...
io Bio Cylembio® Phase 3 Trial Shows Clinical Improvement, Narrowly Misses Significance
IO Biotech’s Phase 3 trial of Cylembio plus pembrolizumab in advanced melanoma narrowly missed statistical significance on its primary...
Forx Therapeutics Launches First-in-Human Trial of Novel Anti-Cancer Drug Forx-428
FoRx Therapeutics has dosed the first patient in a Phase 1 trial of FORX-428, an oral PARG inhibitor, in...
FDA Accepts Arvinas’s New Drug Application for Advanced Breast Cancer Treatment
The FDA accepted Arvinas and Pfizer’s New Drug Application (NDA) for vepdegestrant, an oral PROTAC estrogen receptor degrader, for...
Dogwood Therapeutics Enrolls First 50 Patients in Halneuron® Phase 2b Trial
Dogwood Therapeutics announced enrollment of the first 50 patients in its Phase 2b trial of Halneuron for chemotherapy-induced neuropathic...
Rheumatologists Anticipate IIM Pipeline Advancements
Inadequate disease control remains a persistent challenge in the management of idiopathic inflammatory myopathies (IIM), particularly for dermatomyositis (DM)...
Paragonix LiverGuard System Reduces Post-Transplant Complications
A propensity-matched analysis of 410 liver transplant patients from the GUARDIAN-Liver Registry showed a 51% reduction in early allograft...
Pharmala, Merhavim Center Partner on MDMA Clinical Trial Data
PharmAla Biotech has delivered over 500 capsules of its LaNeo 40mg MDMA to the Merhavim Mental Health Centre in...
Poltreg Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes
PolTREG has dosed the first patient in a Phase 2 trial of PTG-007, an autologous cell therapy for pre-symptomatic...
Sonnet Biotherapeutics Expands Ovarian Cancer Dose Escalation Trial
Sonnet BioTherapeutics reports two out of three patients with platinum-resistant ovarian cancer (PROC) achieved a partial response (PR) in...